Member Info for EmeraldCarrots

FrankyS1971.

You see upset? Did they not forecast break even Q1 2026?

Looking Genedrive over to see the potential then THEY must be stark raving mad! I mean NUTS.

But that would be the crown jewels. Still Genedrive would have the rest of the World.

But that would be the coown jewels.

FrankyS1971

"12 x £325,000 ?? EC - where does it say that this amount is monthly and not annual exactly????"

cheers

====================

Genedrive PLC Half-year Report

Interim results to 31 December 2024

Cash of £1m as at 20 March.

Equity fundraise of up to £1.25m

£2.25m basically from 20th March 2025 for running the Plc.

===============

Genedrive PLC Trading update 11th August 2025.

Cash at bank 20th August approx.. £700k.

£2,250,000 - £700K = £1,550,000 loss in 5 months.

= £1,550,000 / 5 = £310,000 loss per month.

£310,000 loss per month.

12 x £310.000 = £3,720,000 loss per annum. With only roughly 15 hospitals using to date.

They have confirmed orders for about another 21 (including 15 or so for the roll out throughout Scotland).

The income is gaining momentum as more hospityals come on board.

All IMHO.

DNA prep with enrichment" for lung cancer as we can see.

https://angleplc.com/laboratory-services/

Molecular analysis:

Next generation sequencing (NGS) dual analysis of CTC-DNA and cfDNA from a single blood tube. Two workflows, both using CTCs harvested using Parsortix technology:

Illumina’s cell-free DNA prep with enrichment and a custom 79-gene panel targeting lung cancer

ANGLE’s proprietary workflow using a 61 gene pan-cancer NGS panel with blocker displacement amplification

See https://angleplc.com/webinars/

Webina dated 6th Feb 2025.

One wonders what uptake this initial dip into dual analysis has received.

One presumes on the Illumina site once you dive deeper into the "Cell free DNA prep with enrichment" one of the suggeted ways to obtain the CTC's to study is by using Parsortix? Must be an option at minimum.

Angle are quietly getting on with it by the looks.

What other cancers are they working on other than the existing lung cancer one?

Plus what other DNA sequencing Companies other than Illumina are making assay panels to work with Parsortix?

All IMHO.

Stocksaint

You re not a Saint that is for sure. Stop mis-leading people.

================

Genedrive PLC Half-year Report

Interim results to 31 December 2024

Cash of £1m as at 20 March.

Equity fundraise of up to £1.25m

£2.25m basically from 20th March 2025 for running the Plc.

===============

Genedrive PLC Trading update 11th August 2025.

Cash at bank 20th August approx.. £700k.

£2,250,000 - £700K = £1,550,000 burnt through in 5 months.

= £1,550,000 / 5 = £310,000 loss per month.

- Your "cash burn of £6m per year is rubbish.

The income is gaining momentum as more hospityals come on board.

All IMHO.

Stocksaint.

BD5Vant, Current visibility in current financial year is for £600k in total revenue. But cash burn is £6m per year! It's almost unbelievable.

==================

Deliberately misleading post by Stocksaint? I make it the monthly expendature minus the incoming revenue is £325,000. Not good by any stretch but 12 x £325,000 = £3,900,000, not £6,000,000. As more and more hospitals are brought on board this will reduce until it turns positive. The Scottish rollout, starting in October should add around 15 hospitals. Orders confirmed to date woud mean around 31 hospitals on board on the next 6 months. That excludes any more orders at all coming in AT ALL.

You have a massive axe to grind stocksaint. I assume you invested in the Covid sp upsurge. It's very unfortunate, financially, that covid reduced so much. I think we are all glad it did though!

All IMHO.

Of course, I have my reservations about AN's leadership and the Chief Commercial Officer, Brett Swansiger's ability. Brett has been at Angle for a few years now I wonder what he has achieved? The lab team come across as competent and highly skilled. The Parsortix machine appears to do what it says and in many cases is the best machine for the job. A good example is this study which as you can see involves some 450 participants:-

https://clinicaltrials.gov/study/NCT06967961?term=parsortix&rank=8

It says this "The methods of analysis will be flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.". So horses for courses as the saying goes.

Angle have gone all quiet now. I suspect (and if they have any sense?) they are pursuing the "Dual Analysis" dare I say angle! LOL. This should be with Illumina and quite possibly if the rumours are correct Roche. AN's problem seems to always have been over confidence in the value of Parsortix. Easy looking back but the Tescos approach (at least to start off with) selling Parsortix might have been better than the Harley Street one. with the basic machine around $55,000 each or so.

We should not forget AN has "pulled the rabbit out of the hat" before with the dual analysis announcement on 4th Jan 2024. I'm hoping he will do it again with a dual analysis tie up with a huge Plc, Illumina being the most likely.

All IMHO.

Financing is not secured. It's not as if they don't have any income. In October the Scottish rollout starts. This is not for running even more tests. It is actual installation at 15 or so hospitals for use 24 hrs a day, 7 days a week. They have the income from the 14 "test" hospital sites as well of course and the cardiovascular ward trial hospitals. Over 30 hospitals in total, excluding any new orders . They would have to do some serious cost cutting but it could be done.

All IMHO.

Would rocket the sp, and that is because the Genedrive MT-RNR1 has been classified as UNIQUE to the USA market. NO COMPETITION, and needed in all the neonatal wards in the whole USA IMHO!

https://genedrive.com/product/mt-rnr1-id-kit/

All IMHO.

I've always thought this should be a top priority, especially to attract USA investors. The FDA Breakthrough Device Designation they got Last July should have been jumbed on!

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Have you been drinking?

Genedrive. It will be vital for them to earmark any finance money for doing the FDA application. It is incomprehensible that a USA medical supply Company have, so far, not spotted the enourmous potential and approached Genedrive to take them out. It is also very surprising that the Directors seemingly did not prioritise this a year or more ago. Presumably money constraints. Getting FDA approval WOULD have the sp soar of that there is no doubt.

All IMHO.

It's a start!

Genedrive. It will be vital for them to earmark any finance money for doing the FDA application. It is incomprehensible that a USA medical supply Company have, so far, not spotted the enourmous potential and approached Genedrive to take them out. It is also very surprising that the Directors seemingly did not prioritise this a year or more ago. Presumably money constraints. Getting FDA approval WOULD have the sp soar of that there is no doubt.

All IMHO.

All IMHO.

If you all work for London South East to keep the amount of posts up. I see you have done a whole 10 posts now.

We live in hope of news. Anything positive would be nice. LOL!

"The pilot, running from October 2024 to April 2025". May, June, July, and now half way through August. Three and a half months and still we wait.

https://www.nw-gmsa.nhs.uk/about-us/our-projects/genomic-networks-excellence/pharmacogenomics-and-medicines-optimisation-genomic-network-excellence/clopidogrel-pilot-project-cyp2c19-genetic-testing-stroke-and-tia-patients

On FDA clearance so it can be sold in the USA. Once available in the USA if neonatal hospitals don't have it they could possibly be sued if a baby goes deaf because the test was not done. I believe it would be a "must have" for every singe neonatal ward in the whole USA. The numbers are staggering.